Insmed secured FDA approval for Brensocatib (Brinsupri), the first treatment for non-cystic fibrosis bronchiectasis (NCFB). This dipeptidyl peptidase 1 (DPP1) inhibitor targets neutrophilic inflammation and offers a novel therapeutic option for approximately 500,000 U.S. patients. The approval followed successful Phase 3 trials demonstrating reduced exacerbations and prolonged disease control. Insmed plans to launch Brensocatib with dosage flexibility supporting personalized treatment, anticipating multibillion-dollar sales. Newco Expedition Therapeutics licensed Fosun Pharma’s Phase II DPP1 inhibitor XH-S004 in a separate deal focused outside Greater China, highlighting ongoing interest in this drug class. These developments mark significant progress in respiratory disease therapeutics and represent a milestone for Insmed and partners in targeting inflammatory lung conditions.